Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 for treatment of cancer cachexia in advanced NSCLC or pancreatic adenocarcinoma
2010-024342-30Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) comparing BYM338 arm with Placebo arm (2 arms). Primary endpoint: Change in thigh muscle volume by MRI. Started Jun 2011; status: completed.
02
Drugs
bimagrumab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2010-024342-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024342-30.